EuBiologics, a South Korean vaccine developer, plans to submit an Investigational New Drug (IND) application for its Alzheimer's therapeutic vaccine in Q3 2026, targeting early license-out to global pharma. The dual-target vaccine, developed via joint venture EuPOP Life Sciences, aims to offer a cost-effective alternative to existing antibody therapies like Leqembi, with annual treatment costs reduced to one-tenth. This development signals a shift toward premium vaccine manufacturing, relevant for overseas buyers seeking innovative, scalable supply-chain partners.
Pipeline and partnership structure
EuBiologics holds development rights through EuPOP Life Sciences, a joint venture with its US affiliate Pop Biotechnologies. The vaccine targets both beta-amyloid and tau proteins using Pop Biotech's SNAP™ nanoparticle antigen display technology combined with EuBiologics' EuIMT immune-enhancing platform. This dual-target approach aims to induce stronger and more stable immune responses.
Cost and convenience advantage
According to a report by EuHwa Securities analyst Ko Seung-beom, the vaccine could lower annual treatment costs to KRW 3-4 million (approx. USD 2,300-3,100), roughly one-tenth of current antibody therapies. Unlike existing treatments requiring frequent hospital visits and lengthy IV infusions, this therapeutic vaccine would require only a few injections per year, significantly improving patient and clinician convenience.
Regulatory and funding milestones
Pop Biotechnologies was previously selected for the US National Institutes of Health (NIH) Small Business Technology Transfer (STTR) program, receiving approximately USD 2.5 million in research funding. This pre-clinical validation supports the vaccine's commercial potential. EuBiologics plans to submit the IND to South Korea's Ministry of Food and Drug Safety in Q3 2026 and use Phase 1 data to pursue early license-out deals with global pharmaceutical companies.
Manufacturing expansion for premium vaccines
EuBiologics' board recently approved a KRW 110 billion (approx. USD 85 million) expansion of its third plant, dedicated to building vial filling infrastructure for premium injectable vaccines. This move extends the company's portfolio beyond traditional public-sector cholera vaccines into high-value segments including Alzheimer's, RSV, and shingles. The company has also initiated research on a Parkinson's disease therapeutic vaccine using the same platform.
What buyers should watch
Overseas distributors and clinic buyers should monitor EuBiologics' IND progress and early clinical data, as the vaccine's cost and convenience profile could disrupt the Alzheimer's treatment market. The company's manufacturing scale-up for premium injectables also signals potential contract development and manufacturing organization (CDMO) opportunities for partners seeking reliable supply of advanced biologic formulations.
Source: Read the original report | Published: June 19, 2026